FDA Assembles Vaccine Experts to Update COVID-19 Formulation

FDA Convenes Experts to Update COVID-19 Vaccine Formulation

The FDA is convening its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on May 28, 2026, to discuss updating COVID-19 vaccine formulations. The primary objective is to recommend a new vaccine composition to target the now-dominant XFG subvariant circulating in the U.S. This upcoming meeting follows a May 2025 VRBPAC recommendation for monovalent COVID-19 vaccines targeting the JN.1 lineage. Vaccine developers Moderna, Sanofi, and Pfizer are scheduled to present updates on their products, with additional input from the CDC and an independent working group from the World Health Organization. All licensed manufacturers have indicated their readiness to produce an XFG vaccine.

• The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet on May 28, 2026, for a full-day session. The committee's primary task is to make a recommendation for an updated COVID-19 vaccine formulation. During the meeting, external experts will hear presentations from the CDC, an independent working group from the World Health Organization, and vaccine developers Moderna, Sanofi, and Pfizer, who will provide updates on their respective products.
• The urgency for this meeting stems from the latest data from the CDC, which indicates that the XFG subvariant has become the dominant type of SARS-CoV-2 virus circulating in the U.S. The FDA's briefing document highlights that SARS-CoV-2 is evolving against an increasingly diverse immune landscape, influenced by varying levels of virus exposure, vaccination adherence, and waning immunity across the country. All licensed manufacturers have confirmed their preparedness to produce an XFG vaccine.
• This advisory committee meeting takes place amidst a period of significant leadership changes and policy discussions within U.S. health agencies. It follows the recent resignation of former FDA Commissioner Marty Makary, a known critic of COVID-19 vaccines, and Health Secretary Robert F. Kennedy, Jr.'s controversial overhaul of a separate vaccine committee. These events underscore a broader context of heightened scrutiny and evolving public confidence in vaccine science.

Addressing the Evolving XFG Variant and Immune Landscape

Current COVID-19 treatment approaches face significant challenges spanning from development limitations to global health equity concerns. The therapeutic landscape remains constrained by insufficient investment in drug development compared to vaccines, with clinical trials showing predominantly negative results and low completion rates. These limitations are particularly pronounced in resource-limited settings where healthcare infrastructure cannot support optimal treatment delivery.

• Limited therapeutic development and clinical evidence - Few high-quality published studies exist, with low trial completion rates and majority showing negative results, reflecting insufficient investment in COVID-19 therapeutics compared to vaccine development

• Absence of effective antiviral options - No commercially available effective antiviral therapies were available as of 2021, with limited specific antiviral options still representing a major treatment gap

• Inequitable treatment impact across healthcare settings - Drugs like dexamethasone may avert 22% of deaths in high-income countries but only 8% in low-income countries, with effectiveness heavily dependent on availability of supportive care including oxygen and mechanical ventilation

• Focus on hospitalized patients with supportive care assumptions - Treatment advances have predominantly targeted hospitalized patients while assuming adequate access to supportive care, limiting applicability in resource-poor settings

• Insufficient early intervention strategies - Limited availability of therapeutics delivered early in infection course that could reduce healthcare needs or infectiousness, which could have significant impact particularly in resource-poor settings facing large epidemics

• Clinical heterogeneity and protocol standardization challenges - Variability in disease severity, emergence of new variants, individual immune responses, and lack of universal treatment protocols complicate therapeutic approaches

• Health equity and coordination gaps - Inadequate attention to social determinants of health and poor coordination of trials for accessible agents in low- and middle-income countries, raising concerns about COVID-19 becoming a neglected tropical disease

VRBPAC Convenes to Update COVID-19 Vaccine Guidelines

Current standard of care for COVID-19 centers on evidence-based antiviral therapies with specific timing requirements and patient selection criteria. The 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America provides comprehensive recommendations for antiviral use in adults with mild to moderate COVID-19, utilizing systematic literature review and GRADE methodology.

Approved Antiviral Monotherapies:
• Remdesivir (Veklury) and nirmatrelvir/ritonavir (Paxlovid) constitute the currently approved antiviral monotherapies against COVID-19
• Remdesivir requires administration within 7 days of symptom onset for a 3-day treatment duration
• Nirmatrelvir/ritonavir must be initiated within 5 days of symptom onset for a 5-day treatment course
• Molnupiravir serves as an additional direct-acting antiviral offering clinical benefits
• These agents significantly reduce viral loads, illness duration, disease severity, and mortality rates

Patient Population Targeting:
• Remdesivir is recommended for hospitalized patients with severe COVID-19 and high-risk patients for disease progression
• Among adults aged ≥65 years receiving antiviral prescriptions, 99% received treatment within 7 days of positive SARS-CoV-2 test or diagnosis
• Nirmatrelvir/ritonavir was prescribed to 80% of adults aged ≥65 years receiving antiviral therapy
• Immunocompromised patients, particularly those with hematological malignancies, require special consideration due to higher risk of prolonged infection

Combination Therapy Approaches:
• Dual antiviral therapy with nirmatrelvir/ritonavir and remdesivir demonstrates effectiveness for protracted SARS-CoV-2 infection in B-cell-depleted patients failing monotherapy
• Combination treatment with monoclonal antibodies in early COVID-19 reduces time to viral clearance when effective variants are selected
• Combined antiviral regimens achieve satisfactory clinical and microbiological outcomes in immunocompromised patients with persistent infection
• Combination strategies represent promising approaches to increase efficacy while minimizing resistance potential

Corticosteroid Integration:
• Remdesivir plus corticosteroids significantly reduces inpatient all-cause mortality compared to corticosteroids alone across the Omicron period
• Combined therapy demonstrates adjusted hazard ratios of 0.77 and 0.79 for 14-day and 28-day mortality respectively
• Mortality reduction reaches approximately 25% overall, with greater benefit observed in elderly populations
• Among hospitalized patients, remdesivir combination therapy reduces mortality from 8.1% to 6.2%

Current Treatment Limitations:
• Major challenges include viral mutation-associated resistance, limited treatment windows, and unequal treatment access
• Need exists for novel compounds with broad-spectrum activity, improved pharmacokinetics, and enhanced safety profiles
• Continued emergence of resistant SARS-CoV-2 variants necessitates adaptable and durable therapeutic strategies
• Optimal interventions should prioritize safety, affordability, ease of administration, and equitable global access

Navigating Public Trust and Vaccine Safety Data

Published safety and tolerability data from extensive clinical trials and real-world surveillance demonstrates that COVID-19 vaccines across all major platforms maintain acceptable safety profiles with predominantly mild to moderate adverse events. The most recent 2024 safety data confirms that most reactions are mild to moderate in severity, resolving within 3-4 days without clinical intervention. Common local adverse events include injection site pain (reported in 71.7% of subjects in some studies), swelling, and erythema, while systemic reactions encompass fever, fatigue, myalgia, and headache. Laboratory derangements such as decreased hemoglobin and elevated liver enzymes have been documented but remain clinically insignificant and self-limiting. Systematic reviews consistently indicate that serious adverse events, when reported, are typically unrelated to vaccination.

Comparative analysis across vaccine platforms reveals distinct safety signatures, with mRNA vaccines showing higher relevance to certain serious adverse events compared to viral vector and inactivated vaccines, though no definitive causal relationship has been established. Serious metabolic, musculoskeletal, immune-system, and renal disorders occur more frequently among inactivated vaccine recipients, while serious gastrointestinal complications and infections are more prevalent with viral vector platforms. Vessel disorders demonstrate increased occurrence with mRNA vaccines, yet comprehensive reviews conclude that all assessed COVID-19 vaccines maintain sufficient safety margins alongside demonstrated efficacy. Dose-dependent patterns show increased adverse event rates after second doses, particularly with mRNA platforms, and younger individuals experience minor reactions more frequently than older populations.

Rare but serious adverse events of special interest include venous and arterial thrombotic events, Bell's palsy, and myocarditis/pericarditis, with documented cases of severe delayed hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis occurring at rates consistent with background population incidence. Neurological complications including Guillain-Barré syndrome, transverse myelitis, and acute disseminated encephalomyelitis remain exceptionally rare and generally treatable. Analysis of heterologous versus homologous vaccination schedules demonstrates no increased risk of serious adverse events, with adjusted incidence rate ratios remaining within acceptable ranges across all monitored safety endpoints. Long-term post-marketing surveillance continues to be warranted, particularly for vulnerable populations including elderly individuals, those with comorbidities, pregnant women, and pediatric populations.

Adapting to XFG: The Next Chapter in COVID-19 Vaccine Strategy

The upcoming FDA VRBPAC meeting to discuss an XFG-specific COVID-19 vaccine formulation marks another critical step in the ongoing battle against a constantly evolving virus. This proactive approach, moving from a JN.1-focused recommendation to one targeting the now-dominant XFG subvariant, underscores the scientific community's commitment to adapting our defenses. The SARS-CoV-2 virus has consistently demonstrated its capacity for viral evolution, with new variants emerging that can evade prior immunity or alter disease severity. Studies have repeatedly shown that vaccine effectiveness can wane over time, particularly against new lineages, making these regular updates essential.

For individuals, this means a continued need to stay informed about vaccine recommendations. While initial vaccine doses provided robust protection, especially against severe disease, the emergence of variants like Omicron has highlighted the importance of boosters. For instance, protection against hospitalization waned even after a third dose of monovalent mRNA vaccines during Omicron periods, emphasizing the value of bivalent formulations. The immunocompromised population remains a particular concern, facing significantly higher risks of hospitalization and disproportionately contributing to healthcare costs, underscoring the need for highly effective, updated preventive measures tailored to their vulnerability.

The pharmaceutical industry, with companies like Moderna, Sanofi, and Pfizer at the forefront, must continue to demonstrate regulatory agility and manufacturing readiness to pivot quickly to new formulations. However, this adaptive strategy is not without its challenges. The risk of waning immunity against future variants and the potential for new strains to exhibit further immune escape remain constant considerations. Furthermore, ensuring equitable and efficient vaccine distribution and uptake across diverse populations, especially those historically underserved or at higher risk, is paramount to truly mitigate the pandemic's impact. This continuous cycle of variant identification, vaccine development, and public health recommendation is likely to define our long-term strategy for managing COVID-19, much like seasonal influenza.